Document is current
Any future updates will be listed below
-
Authors
Vandewouw, Marlee M. https://orcid.org/0000-0002-4505-0306
Syed, Bilal
Barnett, Noah
Arias, Alfredo
Kelley, Elizabeth https://orcid.org/0000-0001-7742-6542
Jones, Jessica
Ayub, Muhammad
Iaboni, Alana
Arnold, Paul D. https://orcid.org/0000-0003-2496-4624
Crosbie, Jennifer
Schachar, Russell J.
Taylor, Margot J.
Lerch, Jason P.
Anagnostou, Evdokia
Kushki, Azadeh https://orcid.org/0000-0003-1510-8818
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
New Frontiers in Research Fund
- License Information
-
More Information
Article History
Received: 20 January 2025
Revised: 2 July 2025
Accepted: 18 August 2025
First Online: 29 August 2025
Competing interests
: AK has a patent for hollyTM (formerly Anxiety Meter) with royalties paid from Awake Labs. AK has received consulting fees from DNAStack and Shaftesbury. EA has received grants from Roche and Anavex, served as a consultant to Roche, Quadrant Therapeutics, Ono, and Impel Pharmaceuticals, has received in-kind support from AMO Pharma and CRA-Simons Foundation, received royalties from APPI and Springer, received an editorial honorarium from Wiley, and has a patent for hollyTM (formerly Anxiety Meter). The remaining authors have no potential conflicts of interest to report.
